Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
exactly Aqua - Where are those doggone share?
It. just. doesn't. add. up.
Thank you by the way for your intelligent posts.
They are very concise - well done
$SNDY
good luck to you
Blueskies
looking forward to hearing the news from Clark - we are way oversold here
Clark Ortiz ?@clarkortiz 23 Nov
GM, Stay close to the company disclosures throughout the next 48 hrs. Clarity of a new SWRF/iPoint agreement much better for SWRF.
Reply
Retweet
Favorite
Expand
Maybe Today? He is not in NYC running with the Bulls for the fun of it. Stay tuned all
blueskies
Hi I am new to this board, I am reading a lot about dilution but it just doesn't add up.
Can anybody tell me where all the shares are?
Thank you in advance for your time and patience
blueskies
Massive dilution coming into the market everybody. 20 million total shares traded the past month alone!!
61,491 shares TODAY!!!
Get out while you still can
blueskies and good luck on your investments
So...Where are the shares?
Solos Endoscopy Retains Emergo Group to be the Authorized Representative for the Importation of Solos Instruments into Europe
Solos Endoscopy Reports Results From Stage 2 of Its ISO 13485 Audit With TUV SUD America
Solos Endoscopy, Inc. Retains Expert Resource to Meet Requirements for ISO 13485 Quality Management System Initiative
blueskies
Where are the shares?
$SNDY
blueskies
I love the all the dilution talks claiming millions and billions of shares hitting the market especially on all of these consistently super high volume days...lol...
I think there were some questions out there asking where all these shares hitting the market are going..... hmmm?
Stronger hands IMO
Oh and BTW
Solos Endoscopy Retains Emergo Group to be the Authorized Representative for the Importation of Solos Instruments into Europe
http://finance.yahoo.com/news/solos-endoscopy-retains-emergo-group-130500796.html
Solos Endoscopy will work with TUV SUD America and Expert Resources to complete the certification to ISO 13485:2003, which will in turn facilitate Solos Endoscopy obtaining the CE Mark on its MammoView[R] devices to sell the MammoView[R] in the European Union
"FOUND NO NON-CONFORMITIES"
Once the documentation has been prepared and TÜV SÜD reviews and approves the required documentation for the sterile devices, TÜV SÜD will certify Solos Endoscopy to ISO 13485:2003 and provide certificates for CE Marking for Solos Endoscopy's sterile MammoView® system devices. CE Marking will allow Solos Endoscopy to sell its endoscopic instruments, including the MammoView® devices to the European Union. The Company expects the entire process to be concluded by the end of the year. Solos Endoscopy plans to market and sell its instruments internationally in 2014.
"Solos Endoscopy is committed to the worldwide distribution of its endoscopic instruments. We believe this dedication will result in increased sales and profits for the Company and its shareholders," stated Robert Segersten, Solos Endoscopy CEO.
Sounds like a crash and burn company to me
No future here....move along...nothing to see here people....
haha
blueskies
Did anybody see this?? This company is going to crash and burn.
What. Are. They. Thinking. ???
11/07/2013
Solos Endoscopy Announces the MammoView(R) Breast Cancer Global Initiative for 2014
10/7/2013
Stage 2 Audit with TÜV SÜD America Expert Resources Report
"FOUND NO NON-CONFORMITIES" WHATTTTT!?!?!
"Solos Endoscopy is now in the process of drafting Technical Files and associated documents for the MammoView ® devices the company intends to sell in Europe." - HOW DARE THEY!!!!!
What is this world coming too? Oh, the Humanity!
Get out while you can everybody - ..........I'll hang back though to make sure they do indeed implode. Just sell your shares at a low price and I'll take care of the rest.
blueskies
Agreed. Still holding on the Breakout Boards too
We all just need to remember that nothing has changed with the companies goals
#12 Solos Endoscopy, Inc. (SNDY) 347% 66 SNDY 0.0015 -0.0001 -6.25% 456,525
Blueskies
Speaking of more eyes reading
We are now making the Most Read CHANGE Boards -
#45 Solos Endoscopy, Inc. 1,451 SNDY 0.0016 -0.0002 -11.11% 301,110
AND
the Most Read LAST HOUR Boards
#42 Solos Endoscopy, Inc. 282 SNDY 0.0016 -0.0002 -11.11% 301,110
AND
Breakout Boards
#16 Solos Endoscopy, Inc. (SNDY) 347% 66 SNDY 0.0016 -0.0002 -11.11% 301,110
You can almost feel it...like something great is about to happen...just thinking out loud of course
blueskies
and..we're buzzing again. MAN..That's Great!!
Buzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzz cloud - check it out
blueskies
Wow!! From #34 to #22 just this evening...
22 Solos Endoscopy, Inc. (SNDY) 321% 61 SNDY 0.0016 -0.0002 -11.11% 301,110
back to work for me - til tomorrow
Good night all
blueskies
DD Must READ It is Phenomenal!!
One of my favorites and most comprehensive.
DD from those here on the board who have been tracking and supporting $SNDY for quite some time now.
Good luck everybody - blueskies and I wish you all well on your investments!!
Other posts can be found out there in cyberspace but out of respect for this board I will not post the link. Those doing their DD will find them :)
Solos Endoscopy Completes Stage 2 of its ISO 13485 Audit with TUV SUD America
BOSTON, MA, August 22, 2013 – (Accesswire) - Solos Endoscopy, Inc. (SNDY) is pleased to announce that TUV SUD America has completed its Stage 2 ISO 13485 Audit with Solos Endoscopy on August 16, 2013. Solos Endoscopy will be certified to ISO 13485:2003, the internationally-recognized standard for quality systems for medical device manufacturers, once it reviews and resolves any corrective actions that were discovered during the final audit.
Solos Endoscopy will work with TUV SUD America and Expert Resources to complete the certification to ISO 13485:2003, which will in turn facilitate Solos Endoscopy obtaining the CE Mark on its MammoView[R] devices to sell the MammoView[R] in the European Union. ISO 13485:2003 certification is also a necessary for the company to sell the MammoView[R] product line in Canada. The Company expects the entire process to be concluded by the end of the year, which will allow the Company to market and sell its instruments internationally in 2014.
Solos Endoscopy retained Emergo Europe to act as the official Authorized Representative in Europe. Emergo will provide Solos assistance related to communications with authorities and importation of Solos instruments in Europe.
Emergo Group will register Solos instruments with the Competent Authorities (Ministry of Health) as required, including the Dutch Ministry of Health. Emergo will act as a liason for Solos Endoscopy between the European Commission and national Competent Authorities. Emergo Europe consultants will assist Solos with a wide variety of regulatory, quality assurance, and distribution.
“We would like to thank TUV SUD America and Expert Resources for their continued support as we accomplish our goal to market Solos instruments worldwide,” stated Robert Segersten, Solos Endoscopy, CEO.
The Solos MammoView[R] Breast Endoscopy System employs advanced microendoscopes and optical technology which gives physicians sharp images of the milk ducts where the majority of breast cancer arises. Solos Endoscopy instruments are FDA approved. Upon Solos Endoscopy’s receipt of its ISO 13485 Certification, the Company will be able to place the CE Mark on its entire MammoView[R] instrument line which will allow the instrument line to be sold globally.
About Solos Endoscopy, Inc.:
Solos Endoscopy is celebrating its 25th Year of providing quality innovative healthcare instruments to Hospitals across the Country. For more than 25 Years, from medical schools to hospitals, surgeons have trusted Solos Endoscopy to develop and market breakthrough technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment and management of disease and medical conditions.
For more information on TUV SUD America visit http://www.tuvamerica.com/ . For more information on Emergo Group visit http://www.emergogroup.com/ .
http://finance.yahoo.com/news/solos-endoscopy...00387.html
UPDATE: DILUTED SHARES ARE NOT HITTING THE MARKET
Diluted shares are not hitting the market...
Since the last dilution we have had 9 up days and 4 down days. The price then was .0024, yesterday we closed at .0031. It is IMPOSSILBE for 29,000,000 shares to be diluted into the market in 13 trading days and the stock price go up 25%. There is no way in hell that could have happend IF those 29,000,000 shares went into the market. Once again it would of also been IMPOSSIBLE to have 9 days the price traded up compared to 4 day traded down. I don't care what anyone says, volume, price, trading action says those 29,000,000 shares did not trade into the market. When companies dilute millions of shares into the market the share price ALWAYS GOES DOWN!!
One other point since they have diluted over 130 million share in the past 7 weeks the price has went from .002 to .003, a 50% increase in price. I've seen several companies dilutes 30-50 million shares and you will typically see a price drop anywhere from 10%-30%. You will never see a company dilute over 130 million shares in 7 weeks and see the price increase 50%. The reason for the increase instead of a decrease, the shares are not going into the market. People need to start to see this for themselves.
Take care my friends,
Mike
Now this is starting to make since how the price moves so easily and how it will move just as easily when big news is announced.
HERES THE FACTS ON PRICE MOVEMENT TO VOLUME RATIO...
Looks like we have been warned over and over and over again that this stock will never go up because of all the diluted shares. Well according to the charts, if we compare price movement and volume the dilution is not hindering the stock price to run.
Lets go to bigcharts and see the facts for ourselves.
http://bigcharts.marketwatch.com/interchart/i...amp;freq=3
Once you open the link go to the left box click timeframe, then click chart range, then click 2 years.
Now lets look at volume and price movement. That is the telling story with the tradeable float. Slide your cursor on the bottom part of the chart and you will see for yourself the volume/date and price.
Date.............Price....Volume
Jan 27,2012 .0008 92,780,424
Feb 3, 2012 .001 138,243,856
Feb 10,2012 .003 148,966,600
Feb 17,212 .008 676,904,500
Total Volume 1,056,895,380 That is over 1 billion shares
traded in 3 weeks.
Float at this time was only 379,000,000
Date.............Price....Volume
March 9, 2012 .004 85,953,790
March 16,2012 .007 146,009,456
March 23,2012 .017 335,275,736
March 30,2012 .018 287,097,184
Total Volume 854,336,166 Over 3/4 million shares traded in
3 weeks and a 350% increase in price. Also remember we had big news that came out on March 23 that drove the price.
Float at this time was only 379,000,000.
Date...........Price....Volume
Feb 1,2013 .004 42,879,750
Feb 8,2013 .004 119,606,072
Feb 15,2013.006 103,673,360
Feb 22,2013.008 92,857,000
Total Volume 359,016,182, thats 58% less volume then the run we had from March 9th thru March 30th. Price increase of 100%.
Float at this time was 640,000,000.
A 41% increase in shares from the March 2012 run and yet the price moved just as easily.
Even the run up the July 18 went from .002 to .0038 on only 105,000,000 shares that day. Up over 80% and with a float of over 850,000,000 shares!!
These are FACTS that can't be dispelled no matter what anyone says. Yes the FACTS are they increased the O/S by 261 million shares during that time. But the FACTS also tells us those shares are not in the open market,(meaning when SNDY is selling these shares someone is buying them instead of them being just dumped into the open float of tradeable shares). If the float was that much bigger it would of taken at LEAST TWICE AS MUCH VOLUME TO MOVE THE STOCK PRICE UP ON THE RUN BACK IN FEBRUARY 2013.
I would agree with what many are saying about them diluting shares if they were being added to the tradeable float. The stock price would be very very hard to move up when you have a much larger float. But the FACTS shown in this chart with the price to volume ratio just do not support that the dilution will kill any run up in price. Sorry but it is simply the facts.
Yes SNDY has been selling shares but a lot of people on this board are buying. And this chart tells us that someone is buying them instad of them being dumped in the open market. Booper, Muff1, Blueski, Mgergo, Pennylanepam, Vert, Elcappy1, Frazier, Ichase01 and many others including myself have been buying millions of shares since February 2012. And the chart says exactly that.
Take care my friends,
Mike
@)-;- Expert resource - GUARANTEES to pass final Audit -;-(@
"ER's approach to Management Systems consulting is very comprehensive, flexible, and affordable. Our consultants maintain a 100% success rate of attaining registration upon first attempt. ER also offers a compliance guarantee! Expert Resource guarantees that your documentation prepared by ER will pass the final audit, regardless of which registrar you choose to audit your management system. Beware of consultants who only guarantee based on the registrar they choose for you."
http://www.expertresource.net/ISO_Systems_index.html
SNDY has state-of-the-art devices and will be primed for exit. Investors seemed to be more concerned with pre milestone activity and timetables without understanding future potential impact they provide. We are headed toward a inflection point where much higher values could be generated.
POSTS THAT DESERVE ANOTHER LOOK
(I know I missed a bunch but this is what I could do in the time I had!)
ICHASE01
Wednesday, August 14, 2013 11:09:33 AM
Summary of President's Letter:
1. Stage 1 Audit with TUV SUD America was completed on 2/26/13.
2. Stage 2 Audit for ISO 13485 is scheduled 8/16/13; once completed and CE certification obtained, MammoView devices will be able to be sold in Canada and EU.
3. Solos Endoscopy has retained Emergo Group as authorized representative in Europe.
4. Core business is development and marketing of medical technology, applications, medical devices and procedural techniques.
5. Assets decreased, but so did liabilities.
6. Positive Net Book Value.
7. Increase of sales from same period last year.
8. Increase in revenues.
9. Expenses decreased as did Net Loss.
10. Stock was issued to CEO, not cash, for salary.
MGREGO
Thursday, August 08, 2013 5:34:23 PM
It is pretty much a given that SNDY common shares or Preferred shares would be part of any path to obtaining distribution channels. The shear size of the increase does immediately give the company enormous flexibility to secure a wide variety of deals.
Any M&A (whether Solos is on either end of the equation) or JV would be contingent/necessary on the company increasing its authorized capital (A/S).
An A/S increase is a necessary part of the equation. The condition is often referred to as an amendment to the Articles of Incorporation.
HIGHFLIER
Dilution is paying for the salaries of the folks at SNDY. We have heard a few hundred times how they are screwing us by living it up on our hard earned money. Well that is simply not the case. You need facts, here it is.
The Company decreased its Net Loss for period ended June 30, 2013 by $471,290. The significant financial improvement from the same period in 2012 is due to the fact that the Company will not be charged again
for the issuance of stock to its CEO to guarantee his contract. This improvement of $450,000, combined with an increase in sales of $26,203, resulted in a significant turnaround for the Company. According to Management, total salaries are only $45,404 or approximately 40% of sales. The Company has spent additional monies on professional fees to complete the TUV Audit which is scheduled to take place on August 16, 2013. Therefore, Operating Expenses going forward should remain constant. The reduction of these onetime expenses, coupled with an expected increase in sales the 3rd and 4th quarters in 2013, should result in a very positive end of the year for Solos Endoscopy.
1. According to this their TOTAL SALARIES(plural)is $45,404.
2. The Company has spent additional monies on professional fees to the past several months that all this dilution by the company was to complete the TUV Audit which is scheduled to take place on August 16, 2013. Well according to this additional money has been spent to pay for obtaining the CE mark. Now recently they have hired Emergo Group. Most likely those 100,000,000 million shares was to pay for their services.
Being told they sold millions of shares for the lavish salaries of the folks at SNDY is simply not true.
HIGHFLIER
THE REAL REASON PAST R/S HAPPENED...
I just want everyone to look at the real reasons that are factual as to why SNDY did 4 past R/S. That is what one has to look at and then see if this is the same company now as it was back during the time. Let's consider what was going on during that time.
Solos Endoscopy made a bad business decision when they bought medical devices from Lifeline Bitechnologies for $4 million dollars during tough economic times.
August 2, 2006
Solos Endoscopy Completes Acquisition of Early Cancer Detection Products From Lifeline Biotechnologies for $4 Million
By: Solos Endoscopy, Inc. via Marketwire News Releases
Solos Endoscopy, Inc. (PINKSHEETS: SLSE) today announced the Company has acquired the Lifeline Biotechnologies' early cancer detection product line for $4 Million in restricted shares of Solos Endoscopy. Solos Endoscopy has obtained medical assets from Lifeline Biotechnologies, which included the MastaScope(TM), First Warning System(TM), OvaScope(TM), and the intellectual properties relative, to those products.
Lifeline Biotechnologies will also receive compensation, in the form of a royalty, once sales of the MastaScope(TM), First Warning System(TM), and OvaScope(TM) exceed $4 Million. Lifeline Biotechnologies, Inc. has announced existing shareholders will receive a dividend in Solos Endoscopy for their support of Lifeline Biotechnologies in the development of these products.
Now that these new technologies have been acquired, Solos Endoscopy plans to continue the testing and development of these products in an effort to add them to the current line of women's health care products currently in development at Solos Endoscopy.
"We are happy that we have completed this transaction successfully," stated Jim Holmes, President of Lifeline Biotechnologies.
"We look forward to adding these products to our growing line of endoscopic devices and feel that they will help enhance our position within the women's endoscopic healthcare market," stated Robert Segersten, President of Solos Endoscopy, Inc.
business.highbeam.com/436102/article-1G1-148999918/solos-endoscopy-completes-acquisition-early-cancer
Here we can all see this was toxic for SNDY when they purchased these products for $4 million dollars when the economy was not doing well. They needed to say focused on what they do best and that is make their own medical devices. It was during this time from Aug. 2006 thur Aug. 2010 that the R/S happened. They did need to do R/S to keep the company going. They made a bad mistake in extending themselves in spending $4 million dollars plus royalities during this time.
They were at least smart enough to realize it was time to do something to correct their mistake in buying this from Lifeline. So they sold the devices back to Lifeline Biotechnologies.
Newsline:
Solos Endoscopy, Inc. Sells Ovascope and Mastascope Product Line to Lifeline Biotechnologies, Inc.
March 20, 2009
BOSTON, /-- Solos Endoscopy, Inc. (Pink Sheets: SNDY) is pleased to announce that the Company has signed an agreement with Lifeline Biotechnologies, Inc. (Pink Sheets: LLBO) to sell the Ovascope and Mastascope product line to Lifeline Biotechnologies for a combination of stock, assumption of debt and other consideration. Solos Endoscopy originally purchased the products from Lifeline Biotechnologies in 2007.
Lifeline Biotechnologies has agreed to assume a convertible debt from Solos, which will result in less dilution for its shareholders. In addition, the sale of the Ovascope and Mastascope will allow Solos to use its resources to support its expanding core business. Solos is currently in negotiations with Lifeline regarding distribution rights to these products once they are finally ready for the market. Solos will continue to focus its efforts in the area of women's healthcare by concentrating on its Mammoview product line, which is currently sold to hospitals nationwide.
"Although we feel that there is great potential in the Mastascope and Ovascope technology, due to the current state of the economy, our resources will be better utilized in strengthening our current product lines to an expanding customer base," stated Bob Segersten, President of Solos Endoscopy, Inc.
http://boston.citybizlist.com/article/solos-e...ogies-in-0
Ok now we have some pretty factual reasons SNDY had to do the prior 4 R/S. And to me it would make perfect sense why SNDY had to do those past R/S. It was because they were in major debt because they made a bad choice in an investment decision to buy these medical devices. It happens to companies all the time, not just Solos Endoscopy. As business owners we want to do things to grow our business and we step out and do things that may not of been so great of an idea. But you have to be smart enough and realize when a mistake has been made and correct it. That is what SNDY did.
Did it hurt those investors back then? Absolutely! But it was their choice to be invested in a company that had MAJOR DEBT. I would of NEVER CHOOSEN TO INVEST in a company with that much debt. It was a BAD decision for ANY INVESTOR AT THAT TIME TO have done that. AND SNDY DID NOT make ANYONE invest in their stock. IT WAS A CHOICE, A VERY BAD CHOICE FOR ANYONE TO INVEST IN A COMPANY WITH THAT MUCH DEBT IN A HORRIBLE ECONOMY!!!!
THAT is the real reason why they had to do those past R/S. Bad debt, plain and simple. You never quite tell the real reason why those past R/S happened. But they have turned the corner and the president has said since last year we would see this thru to get the CE mark and then have global distribution of their products bringing value to the share holder. That is about to happen. The future growth of SNDY is about to happen.
HIGHFLIER
both know it was not cheap to hire these companies to get the job done for Solos. It cost money, a lot of money. When I look at these 3 companies, especially Emergo, I think you said it best, PRICELESS. Solos has positioned themselves with some very good companies that can take them to the next level. I just believe the possibilites are endless where this could go, examples: merger/acq./buyout/increase revenue.
People keep thinking only the Mammoview. But I keep looking also at the SteriTap and this article on how huge this market is and the major companies little old Solos is mentioned with:
SOLOS ENDOSCOPY MENTIONED IN $3.6 MILLION LAPAROSCOPIC ARTICLE...
US Laparoscopic Device Market to Grow Moderately to Nearly $3.6 Billion by 2017 Growth Driven by Increasing Demand for Minimally Invasive Procedures, According to Millennium Research Group
January 14, 2013—Toronto—According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the United States market for laparoscopic devices will grow moderately, reaching a value of $3.59 billion by 2017. Growth will come largely from expanding procedure volumes, as the demand for minimally invasive techniques continues to grow. Direct energy, hand assist and single-port devices will grow most quickly.
Laparoscopic procedures will grow significantly faster than open surgeries through 2017 as surgeons continue to take advantage of the patient benefits of laparoscopic techniques, such as faster recovery, less post-operative pain, and better cosmetic results. Bowel resections will be the fastest growing laparoscopic procedure, followed by sleeve gastrectomies and hernia repairs. Sleeve gastrectomies will grow at the expense of gastric banding, which has suffered from safety and efficacy concerns.
Single-port procedures will grow strongly, driven by uptake in high-volume procedures such as cholecystectomies and appendectomies. These are procedures where surgeons are either extremely experienced with laparoscopic techniques, or where the anatomy lends itself to straightforward access from the umbilicus.
Robotic techniques will also show strong adoption in urological and gynecological procedures, particularly in prostatectomies, partial nephrectomies and hysterectomies.
“Outside of these growth segments, there is a strong emphasis on cost cutting,” said MRG Analyst Chantal Dougan. “Reusable and reposable products have taken ground from disposable products, particularly in the access device and hand instrument segments. While disposable products generate higher per-procedure revenues, over the next few years the conversion to reusable devices will aid revenues, as facilities invest in entire sets of reusables.”
CareFusion, Solos Endoscopy and Integra LifeSciences all launched modular reusable hand instruments in 2012 to combine convenience with cost-savings.
Here we see Solos is getting mentioned with some big name companies. These people writing these article know the products SNDY has. And out of all the companies they could of mentioned they DID MENTION SNDY!! SNDY spending the money last year to bring out new products is going to pay off big time. They know their market and are taking every step to position themselves to be a player in this market. And a company like Emergo Group can get this type of product into a Global market quickly.
HIGHFLIER
I SURE HOPE EMERGO GROUP IS OUR PARTNER....
Emergo Group consultants will assist Solos with a wide variety of regulatory, quality assurance, and distribution. Who will help us in distrubution? A group of their consultants.
So here is one of their distribution consultants
David Christie, BSc, MBA
Distribution Consultant
David Christie is a highly accomplished President and Chief Executive Officer with a proven ability for commercializing technology, facilitating change and increasing shareholder value by delivering compelling financial results. Unique combination of experiences in early stage start-ups, turnarounds, revenue and profit acceleration, mergers and acquisitions across various industries, including environmental, information/communication technologies and medical devices. Mr. Christie’s strengths include implementing strategic change – quickly analyzes the current situation, creates a compelling vision for the future, documents the action plan to move from here to there and executes on the plan with tenacity and precision; delivering financial results – very adept at improving revenue and profit performance through sustainable growth and with appropriate financing; effectively commercializing technology – understands the challenges of turning brilliant concepts in to inventions, creating an effective intellectual property portfolio, overcoming regulatory, reimbursement, quality, manufacturing and logistic challenges, to deliver products to market and realize double-digit returns on investment, especially with innovative new technologies.
EXPERIENCE:
Christie Consulting Services – 2009 to present
Christie Consulting is a sole proprietorship dedicated to helping early-stage and emerging technology companies expand their business. By working with the client’s senior executives in a collegial, advisory and consultative capacity, Christie adds real value by objectively analyzing their business problems, identifying opportunities to accelerate growth and rolling up his sleeves to make results happen. Leveraging his broad and deep experience, he is able to contribute quickly and effectively. Clients include:
• Romich Medical – very early stage, exploring new gynecological applications for existing medical devices
• ARC Pharmaceuticals – early pre-clinical commercial stage, assessing clinical markets here and abroad
• Emergo Group – international regulatory and distribution firm, providing Canadian market assessments
• Hemosonics – start-up stage, advisor to the CEO on all aspects of technology commercialization
So what about the president of Emergo Group:
René van de Zande
President & CEO
René is responsible for all operations of the Emergo Group of companies worldwide. René founded Emergo Group in 1997 and as its President & CEO, he has a consistent record of delivering results in growth, revenue, operational performance, and profitability. Today, he spearheads the international expansion of Emergo Group's operations and service offerings, and provides guidance and support to Emergo Group teams on five continents.
www.massdevice.com/emergo-group-doubles-office-space-accommodate-growth
Emergo Group doubles office space to accommodate growth
Emergo Group, an international regulatory consulting firm, has completed a move into its new headquarters in downtown Austin, leasing more than 13,000 square feet at 816 Congress Avenue.The expansion comes in response to strong demand for the company’s services from medical device manufacturers in the US, Canada and Europe. Emergo Group specializes in assisting medical device companies with US and international regulatory compliance. The company currently employs 55 people at its headquarters in Austin, with plans to continue hiring throughout 2013.
Asked about the driving factors for growth at the company, Emergo Group President and CEO Rene van de Zande notes: “We’re seeing strong demand from companies that want to expand overseas, but might have been intimidated by the regulatory process. That’s especially true in challenging markets such as China, Brazil, Japan, Mexico and Russia, where having local expertise is key. We now have offices in 23 countries, which allows us to help our 2,500 clients grow by accessing markets they might not otherwise have considered.”
Emergo Group plans to expand throughout 2013, with new offices planned for the Middle East, South America and Southeast Asia.
“We don’t see things slowing down. Healthcare spending continues to rise, especially in fast growing markets like Brazil and China. Medical device companies in the US and Europe are looking for ways to boost the top line and the rate of growth in those countries far exceeds what they can expect in their home markets,” notes van de Zande.
About Emergo Group
Emergo Group is an international medical device consultancy serving medical device companies in 55 countries worldwide. The firm assists manufacturers with medical device registration, quality system compliance, clinical trials, in-country representation, reimbursement and distributor search consulting. The company was founded in 1997 and can be found online at www.emergogroup.com
Emergo Gruop knows people on top of people. They are beyond connected across the world. If they have a product then it will have the attention of the companies they distribute to. The possibilities are endless with how all this will unfold with SNDY over the next 2-4 months.
HIGHFLIER
LOOKS LIKE SNDY JUST STEPPED UP THEIR GAME...
in the hiring of Emergo Group. SNDY is taking this final audit as serious as they can. Not only do they have Expert Resources to over see this audit but have now brought in Emergo.
What is Emergo role? Here we go:
ISO 13485 Audits for Medical Device Companies.
Medical device manufacturers are required to regularly conduct an audit of their ISO 13485 compliant quality management system. Emergo Group conducts these fully independent quality system reviews for companies that are already ISO 13485 certified as well as for firms about to undergo their initial ISO 13485 certification audit by a Notified Body or Registrar.
Not only that but look how well Emergo takes care of their customers once hired:
Emergo Group provides the following ISO 13485 auditor services:
These ISO 13485 audits help determine the actual status of your current quality management system and processes:
•Off-site review of your current QA/RA documentation prior to your on-site ISO 13485 audit by a Notified Body or Registrar
•Systematic and independent process audit to determine conformity or nonconformity of your Quality Management System to ISO 13485:2003 requirements
•Review of your internal documentation to verify that all requirements have been addressed
•Actual verification of ISO 13485 audit requirements through review of objective evidence
•Physical verification of compliance via interviews and fact-based observations to confirm quality system requirements
•Evaluation of current special controls or validated processes; knowledgeable in various processes such as sterilization, clean-rooms, or software systems
Emergo Group also provides on-site ISO 13485 auditor training in order for clients to effectively audit their own quality systems. Our training is classroom-based and teaches your employees how to become ISO 13485 internal auditors to ensure proper functioning of your QMS. Key topics of the training include why ISO audits are required, planning an internal audit, as well as conduct and performance issues related to ISO 13485 internal audits.
CE Certification – CE Mark Certification for Medical DevicesSee all regulatory consulting services and medical device registration services.
In order to commercialize medical and in vitro diagnostic devices in the European Union, manufacturers must obtain CE Marking certification and affix the CE marking as part of their device registration efforts.
CE Marking certification verifies to EU regulators that your device meets all requirements of the Medical Devices Directive (MDD), In Vitro Diagnostic Device Directive (IVDD) or Active Implantable Medical Device Directive (AIMD) as they apply to your product. You must obtain CE Marking certification prior to marketing, distribution and sale of your product in any EU member state.
You are solely responsible as the medical device manufacturer for maintaining compliance with EU directives and securing CE Marking certification for your product, regardless of whether you outsource any or all components of your manufacturing operation.
Qualifying for CE certification and marketing your medical device in the EU requires the following steps:
1.Prepare a CE Marking Technical File or a Design Dossier for a Class III device that includes data proving compliance with the MDD, IVDD or AIMD.
2.Obtain your CE Marking certificate from a Notified Body.
3.Select and appoint a European Authorized Representative to act on your behalf within the EU.
4.Register your medical device with the appropriate Competent Authority, if necessary.
Completion of these requirements allows you to claim CE Marking certification for your device.
Looks like to me SNDY just took care of #3 with todays news.
Emergo Group has a well-established presence in the EU, with offices in the UK, Germany, France and the Netherlands. We have assisted hundreds of medical device manufactures with their CE Marking certification efforts. Services we provide to help you obtain CE certification include product classification; technical file and design dossier preparation; ISO 13485 quality system implementation and auditing; and ISO 14971 risk assessment and management.
Why choose Emergo Group as your ISO 13485 consultant?
With over 20 local offices worldwide, Emergo Group has helped hundreds of medical device and IVD manufacturers implement quality systems that meet the ISO 13485 standard. Our team of experienced ISO 13485 consultants have implemented numerous quality management systems for companies manufacturing a wide range of medical devices.
Our system has been proven to work efficiently and we have been through the process with many medical device and IVD companies that we guarantee you will pass your first ISO certification audit if you follow our plan.
•We fully customize ISO 13485 quality systems for our clients.
•Our ISO 13485 consulting and project management teams will work closely with you to ensure that your quality system is implemented on time and on budget.
•On-site ISO 13485, CE Marking, and Canadian Medical Devices Regulations training for your key employees is included in the cost of an Emergo Group quality system.
•All of our projects are based on a fixed price.
CE Mark Consultants and CE Marking for Medical Devices
Before you can sell a medical device or IVD within Europe, you must obtain CE Marking certification and place a CE Mark (CE Marking) on your product. The CE Marking for medical devices is not a quality mark nor is it intended for consumers. It is a legally binding statement by the manufacturer that their product has met all of the requirements of the Medical Devices Directive (MDD 93/42/EEC), In Vitro Diagnostic Device Directive (IVDD 98/79/EC) or the Active Implantable Medical Device Directive (AIMDD 90/385/EEC), where applicable. If a Notified Body is required, the Notified Body's four-digit number would appear below the CE Marking symbol.
CE Marking Checklist:
The Medical Devices Directives state that companies must do the following before they can place the CE Marking on a medical device or IVD:
•Compile a medical device CE Marking Technical File (or Design Dossier for Class III) with evidence of compliance to the Medical Devices Directive (or the IVD/AIMD Directives).
•Receive a medical device CE Mark certificate from a Notified Body if Class I with Measuring or Sterile function, Class IIa, IIb, or III, or if Annex II, List A; Annex II, List B, or self-testing IVD.
•Appoint a European Authorized Representative if you have no physical location in Europe.
•Register medical devices with the EU Competent Authorities, where applicable.
Only after these CE Marking requirements are satisfied are you allowed to place the CE Marking on your medical device.
Our CE Marking Services:
Emergo Group has assisted hundreds of companies with medical device CE Marking. Our services include:
•CE Marking Technical File or Design Dossier compilation and review.
•Verification of Essential Requirements.
•Product classification and identification of applicable standards for medical devices.
•Implementation and maintenance of ISO 13485 quality systems.
•Product labeling and packaging review.
•Risk assessment and management (ISO 14971).
•Development of Vigilance and Post Market Surveillance including Vigilance Standard Operating Procedures and Processes.
•Authorized Representative for Europe.
Our quality management systems can meet European CE Marking & other international requirements
Emergo Group can develop a compliant quality management system by applying ISO 13485:2012 to ensure you meet the quality system requirements for Europe. Each system is customized for the manufacturer and can not only ensure compliance to the European Directives for Medical Devices (CE Marking), but also to the Canadian Medical Devices Regulations, United States FDA QSR, Australian TGA requirements, and Japanese Pharmaceutical Affairs Law.
This place is like a Wal-Mart for your one stop shop for all your shopping needs.
Medical Device Logistics ConsultingEmergo Group can assist you with determining the best solutions for shipping your products. When exporting products many medical device companies start by shipping orders direct to distributors or customers. However, as the frequency of orders and order volumes increase it may become lucrative to consolidate orders in bulk shipments or to establish a suitable warehousing arrangement.
Warehousing & Transportation
In situations where companies are shipping direct to multiple distributors or customers, consolidation of these shipments may result in significantly lower shipping costs. And instead of requiring each distributor to keep a minimum inventory level, you as the supplier can decide to keep products warehoused in a centralized location to reduce total inventory levels in the supply chain while maintaining the option to ship next day to the distributors and customers. Results are cost savings in the supply chain, higher service levels to distributors and customers, and increased market share.
When importing products into Europe and warehousing these products in a centralized location, customs duties and value added tax (VAT) apply.
Customs Duties and Value Added Tax (VAT)
Postponement of customs duties can be arranged by warehousing your products in a customs bonded warehouse for an unlimited period of time. During this period no customs duties are due. Customs duties at import need to be paid when the goods are actually imported into the free circulation of the European Union.
Value Added Tax (VAT) is due upon import of products into the European Union and varies per EU country from 15-25%. This is a supply chain tax, and is refundable to businesses, usually by submitting a quarterly VAT return.
Finding and selecting warehousing & transportation partners
When looking for a third party logistics provider for your European warehousing and transportation needs, we can assist you with the following:
Step 1: Determine your medical device logistics needs
Depending on if you are starting up or optimizing your logistics operation(s), your needs can range from a distribution location to warehouse, pick, and ship your products to a full service value-added logistics facility where products can be assembled or customized to the specific needs of your customer base. The choice is yours! It is also possible to select a logistics provider as your fiscal representative.
Step 2: Identify potential EU logistics providers
Through our extensive logistics experience and existing network we are very familiar with the capabilities of logistics service providers specialized in medical devices. Based on your logistics needs we can identify the logistics providers that best fit your needs.
Step 3: Meet with potential logistics partners
Seeing is believing! We can set up on-site meetings for you with logistics providers that fit your needs and if required accompany you on these visits.
Well we don't know what it cost to hire Emergo Group, but I can say this, job well done SNDY for hiring such a great company to take this stock to the next level. If you had to sell some shares to make this happen, you spent our money well. I for one never questioned what was happening behind the doors at SNDY. I guess you can say the quite period is now over. I have said for the past 4 months when they have something of importance to tell us they will. I want to thank all the longs that has believed in SNDY over the past year and contributed to this board. I guess all those people spending 1.6 million dollars in SNDY preferred shares believed in them as well. We all know they was betting on the future of this company as well.
TANGERINE
Thursday, August 15, 2013 12:13:17 AM
My conclusion thus far.
The CE mark is a significant milestone. Those on both sides of the argument seem to clearly believe this. With all of the arguments against SNDY, it is clear all believe this to be a big achievement for the company and a lot of money and dilution has gone into ensuring this would happen. So all sides including the company believe this is a big achievement.
Will this CE mark generate significant revenue? Not by itself but it opens markets. Who will be selling this product and who will be buying these products? Who knows at this point. I haven't seen a real answer but it would be a prerequisite to sell the company or merge.
I also don't see anyone arguing that mammoview does not work. So that would be the biggest and best argument to me but it is pretty obvious to me and from reading some of the technical docs, that it probably does work. How come it hasn't been picked up more my others, journals, every hospital in the free world wanting it? Does make you wonder.
I don't see any real short volume and I am not sure you even could short this stock. The downside and upside and the fees probably make this a poor choice.
Is the argument really about a trading opportunity and entry price? Probably, at least it would seem that way.
Buyout? For the tech maybe but the trading wouldn't indicate it so far from what I can see but maybe with CE mark as some are predicting.
Will I buy some more shares? Probably
AQUA
Thursday, August 15, 2013 1:24:01 AM
To bring this into perspective, Solos management realized a long time ago that their products have not met much success in the US healthcare system in terms of revenues and profitability. Their strategic initiative objective was to open Solos to new markets. But the only barrier to entry into the markets in Europe and Canada was obtaining the expensive CE Mark certification. In the process, Solos had to make sacrifices, which were unfortunately at the expense of shareholders after multiple attempts of dilution to their stock. Keep in mind that management's ambition to pursue the CE Mark is valid given the survival of the company is at stake due to least spectacular product sales. With one day away, we await a defining moment in Solos history and its existence as a global company with the purpose of saving lives. Cheers!
SimmerDownNow
Shh... there's an audit going on.
Go SNDY!
EKIM88
ELCAPPY1
3 Month Daily Chart
200MA Leveling out as Resistance...
50MA Turning up for higher levels of support...
Keep in mind what happens when the 50MA crosses above the 200MA with stellar news to back it... Future short term press releases, ISO 13485 (2+yr process), C.E. Certification (2+yr process), Limited Dilution (ISO & CE paid for), New partnerships, Merger, Acquisitions, Share buyback, Retirement of shares, Dividend...
2 Year Daily Chart
Please take a look @ January 2012. This 1000%+ run to the end of March was caused only by the ANTICIPATION of the Stage 2 Audit August 16th 2013... Please take note to the mid March Golden Cross...
2 Year Weekly Chart
EXTREMELY BULLISH
RSI 49.04
20MA RED
50MA BLUE
SNDY PR’s 2008 - 2013
06/06/2008 SNDY Completes Stock Split and Changes Symbol to SNDY
10/02/2008 SNDY and Its Products Appear in Worldwide Global Endoscopic Systems Market Report
10/08/2008 SNDY Posts First Six Months Financials of 2008 on Pinksheets.com
10/14/2008 SNDY in Final Stages to Upgrade Pink Sheet Status from Limited to Current Information
10/20/2008 SNDY Reports an 18% Increase in Sales during 3rd Quarter of 2008
10/23/2008 SNDY Applauds American College of Surgeons Review of Advanced Breast Cancer Detection at 94th Annual Clinical C
10/30/2008 SNDY Mammo View(TM) System Now Used in Women's Hospital of Baton Rouge, LA
11/06/2008 SNDY Receives Purchase Order from Connecticut Hospital
11/14/2008 SNDY Mammo View(TM) System Introduced in Puerto Rico to Promote Breast Health
11/20/2008 SNDY Receives Purchase Order from Clarian Health Partners for Mammo View(TM) System
12/10/2008 SNDY Increases Sales Revenue for October 2008 by Over 10% as Compared to Last Year
01/06/2009 SNDY Receives Purchase Order from Cleveland Clinic
02/11/2009 SNDY Posts First Nine Months Financials for 2008 on Pinksheets.com
02/19/2009 SNDY MammoView(TM) Featured in December Issue of Surgical Products Magazine
02/24/2009 SNDY Breast Endoscopy System Featured in January Issue of Outpatient Surgery Magazine
02/26/2009 SNDY Receives Purchase Order from Major Connecticut Hospital for the MammoView(TM)
03/03/2009 SNDY Successfully Completes FDA Inspection
03/20/2009 SNDY Sells Ovascope and Mastascope Product Line to Lifeline Biotechnologies
03/24/2009 SNDY Receives Purchase Order from Leading San Diego Healthcare Provider
04/02/2009 SNDY Develops Specialized Endocoupler for the MammoView(TM)
09/10/2009 SNDY Receives Purchase Order from One of the Major Healthcare Systems in Missouri
09/17/2009 SNDY Receives Purchase Order from the National Cancer Institute
09/21/2009 SNDY MammoView(TM) Product Line Receives New Purchase Orders Primarily from Prestigious Teaching Hospitals
09/23/2009 SNDY Receives Purchase Order from a University Teaching Hospital in Arkansas
09/29/2009 SNDY Receives Purchase Orders from Leading New York City Healthcare Center
10/06/2009 Small Company Offering and Sale of Securities Without Registration (D)
10/07/2009 SNDY MammoView(TM) Product Line to be demonstrated at the 95th Annual American College of Surgeons Clinical C
10/14/2009 SNDY FDA Approved MammoView(TM) Product Line to Obtain CE Mark
10/16/2009 SNDY Receives Multiple Purchase Orders for its MammoView(TM) Product Line
10/23/2009 SNDY Receives Additional Purchase Orders from National Cancer Institute and National Institute of Health for it
10/27/2009 SNDY Receives Purchase Orders from BJC HealthCare for its MammoView(TM) Product Line
10/29/2009 SNDY Receives Purchase Orders from University of California, San Diego Medical Center for its MammoView(TM) Pro
11/03/2009 SNDY Receives Purchase Orders from Catholic Health Initiatives for its MammoView(TM) Product Line
11/05/2009 SNDY Has Retained Services of Experienced Medical Marketing Firm for a 2010 Campaign
11/11/2009 SNDY Breast Endoscopy System Featured in November Issue of Healthcare Purchasing News Magazine
12/09/2009 SNDY Reports Sales Increase for October 2009 and November 2009 as Compared to Same Two Months in 2008
12/18/2009 SNDY Makes Significant Design Improvement to Its MammoView(TM) Ductoscope
12/23/2009 SNDY Outlines Marketing Strategy for 2010 Campaign
12/30/2009 SNDY Set to Increase Business through Sales and Product Development in 2010
01/15/2010 SNDY Breast Endoscopy System Featured in February Issue of General Surgery News
01/22/2010 SNDY Reports a 9% Increase in Sales for the 4th Quarter 2009 as Compared to 4th Quarter 2008
02/05/2010 SNDY Retains Expert Resource to Meet Requirements for ISO 13485 Quality Management System Initiative
02/16/2010 SNDY Set To Develop New Polymer Dilator For MammoView(TM) System
03/18/2010 SNDY Granted U.S. Trademark for MammoView(R)
04/13/2010 SNDY Successfully Completes Phase One Requirements for ISO 13485 Quality Management System Initiative
04/16/2010 SNDY Posts Financial Results for Year Ending 2009
05/21/2010 Appoints Experienced CFO To Financial Leadership Amidst Growth
05/26/2010 SND Increases Revenues by 10 Percent for First Quarter 2010 as Compared to First Quarter 2009
06/15/2010 Develops Relay Lense Adapter System For MammoView® Product Line
06/24/2010 Breast Endoscopy System Featured in July/August Issue of The Breast Journal
07/13/2010 SNDY Reports a 30% Increase in Sales for June 2010 as Compared to June 2009
08/26/2010 SNDY Reports Revenues for First Six Months of 2010
09/21/2010 SNDY to Hold Annual Shareholder Meeting September 28, 2010
09/30/2010 SNDY Announces Results of 2010 Annual Shareholder Meeting
10/27/2010 SNDY Revenue Grows 34.8% for Third Quarter 2010
11/19/2010 SNDY Announces Recapitalization Plan for 2011
01/06/2011 SNDY Trends toward Strong Continued Growth in 2011
01/27/2011 SNDY Reports $90,005 in Sales Revenue for Fourth Quarter 2010
02/10/2011 SNDY Reports $34,291 in Sales Revenue for January 2011
02/23/2011 SNDY To Introduce New Urology Instrument Line
03/24/2011 SNDY Strengthens Current Line of Laparoscopic Instruments
04/19/2011 SNDY Decreases Net Loss by Over $1 Million
06/14/2011 SNDY Receives Multiple Purchase Orders From Major Cancer Institutes and Research Centers
06/22/2011 Statement of Beneficial Ownership (SC 13D)
06/30/2011 SNDY Enters Multi-Billion Dollar Veterinary Market with Launch of Revamped Endoscopic Veterinary Product Line
06/23/2011 SNDY To Launch New Corporate Website
07/07/2011 Statement of Beneficial Ownership (SC 13D)
07/20/2011 SNDY MammoView® System Proves Crucial to Early Breast Cancer Detection
08/23/2011 SNDY to Reduce Debt by Over $620,000
09/15/2011 SNDY Reports 32% Increase in Breast Endoscopy Sales
09/23/2011 SNDY to Market its MammoView® Breast Endoscopy Components to US Hospitals
10/06/2011 SNDY to Support National Breast Cancer Foundation With Sales of Its MammoView® Breast Endoscopy Components to US .
10/21/2011 SNDY Finishes the 3rd Quarter Strong
11/03/2011 SNDY Goes Google
11/17/2011 SNDY Poised for Tremendous Growth in Multi-Billion Dollar Endoscopic Market
11/22/2011 SNDY Finishes the 3rd Quarter With a Net Profit
12/22/2011 SNDY Reports Significant Sales From Its MammoView® Instrument Line
12/29/2011 SNDY is Primed for Growth in 2012
02/14/2012 SNDY Announces Retirement of 150 Million Common Shares
02/14/2012 Panache Beverages (WDKA) Presence Solid in the State of Florida
03/02/2012 SNDY Successfully Completes Level I FDA Inspection
03/16/2012 SNDY to Launch New SteriTAP™ Endoscopic Instrument Line
03/22/2012 SNDY and Opko Health Benefit From Booming Medical Equipment and Supplies Industry
03/30/2012 SNDY Reduces Net Loss by More Than $688,000
04/25/2012 SNDY Reduces Liabilities by More than $570,000
05/04/2012 SNDY to Finalize ISO 13485 Certification and CE Mark Initiative with Expert Resource for Endoscopic Instruments
04/30/2012 SNDY Sales Increase by 16% for First Quarter 2012
05/16/2012 SNDY Posts Net Profit for First Quarter 2012
05/23/2012 SNDY Releases ISO 13485 Certification and CE Mark Schedule With Work to Begin May 29
06/13/2012 SNDY Reduces Inventory Cost and Improves Gross Profit Margin for Second Quarter 2012
06/19/2012 SNDY to Expand Internationally its MammoView® Breast Endoscopy Product Line
07/13/2012 SNDY Begins Marketing the New SteriTAP(TM) Endoscopic Instrument Line
07/25/2012 SNDY Bariatric Instruments Are Now Available
08/16/2012 SNDY Posts Total Assets of $2,426,883 for Period Ended June 30, 2012
08/21/2012 SNDY Retains TUV SUD America to Complete ISO 13485 Certification and Audit
09/27/2012 SNDY Celebrates 25 Years of Quality Innovative HealthCare for the Multi-Billion Dollar Endoscopic Market
10/11/2012 SNDY Reports Significant Progress on ISO 13485 Certification and Audit
10/24/2012 SNDY Manufacturer to Conduct New Testing to Increase Sterilization Life for its MammoView® Breast Endoscopy
11/08/2012 SNDY Sales Increase by More than 35% for the Month of October
11/14/2012 Quarterly Report
11/15/2012 SNDY Reports Book Value of $2,393,522 for Period Ended September 30, 2012
12/14/2012 SNDY Sales Increases by More than 53% for the Month of November, 2012
12/14/2012 Attorney Letter with Respect to Current Information
12/14/2012 Quarterly Report
01/04/2013 SNDY Management Announces Goals for 2013
01/16/2013 SNDY Finishes 2012 Strong
01/24/2013 SNDY and TUV SUD America Schedule Stage 1 ISO 13485 Audit for February 26, 2013
03/04/2013 Officer/Director Disclosure
10:06 a.m. June 12, 2013
Solos Endoscopy and TUV SUD America Schedule Stage 2 ISO 13485 Audit for August 16, 2013
1:01 p.m. July 18, 2013
Solos Endoscopy's MammoView(R) System Offers Women Early Breast Cancer Detection
9:06 a.m. Aug. 2, 2013
Solos Endoscopy Retains Emergo Group to be the Authorized Representative for the Importation of Solos Instruments into Europe
Also Thank you to our friend Highflier! His postings and DD are unmatched.
THIS SHOULD BE OF ENCOURAGEMENT TO US...
HERES THE FACTS ON PRICE MOVEMENT TO VOLUME RATIO...
Looks like we have been warned over and over and over again that this stock will never go up because of all the diluted shares. Well according to the charts, if we compare price movement and volume the dilution is not hindering the stock price to run.
Lets go to bigcharts and see the facts for ourselves.
bigcharts.marketwatch.com/interchart/i...amp;freq=3
Once you open the link go to the left box click timeframe , then click chart range , then click 2 years .
Now lets look at volume and price movement. That is the telling story with the tradeable float. Slide your cursor on the bottom part of the chart and you will see for yourself the volume/date and price.
Date.............Price....Volume
Jan 27,2012 .0008 92,780,424
Feb 3, 2012 .001 138,243,856
Feb 10,2012 .003 148,966,600
Feb 17,212 .008 676,904,500
Total Volume 1,056,895,380 That is over 1 billion shares
traded in 3 weeks.
Float at this time was only 379,000,000
Date.............Price....Volume
March 9, 2012 .004 85,953,790
March 16,2012 .007 146,009,456
March 23,2012 .017 335,275,736
March 30,2012 .018 287,097,184
Total Volume 854,336,166 Over 3/4 million shares traded in
3 weeks and a 350% increase in price. Also remember we had big news that came out on March 23 that drove the price.
Float at this time was only 379,000,000 .
Date...........Price....Volume
Feb 1,2013 .004 42,879,750
Feb 8,2013 .004 119,606,072
Feb 15,2013.006 103,673,360
Feb 22,2013.008 92,857,000
Total Volume 359,016,182, thats 58% less volume then the run we had from March 9th thru March 30th. Price increase of 100%.
Float at this time was 640,000,000.
A 41% increase in shares from the March 2012 run and yet the price moved just as easily.
Even the run up the July 18 went from .002 to .0038 on only 105,000,000 shares that day. Up over 80% and with a float of over 850,000,000 shares !!
These are FACTS that can't be dispelled no matter what anyone says. Yes the FACTS are they increased the O/S by 261 million shares during that time. But the FACTS also tells us those shares are not in the open market ,(meaning when SNDY is selling these shares someone is buying them instead of them being just dumped into the open float of tradeable shares). If the float was that much bigger it would of taken at LEAST TWICE AS MUCH VOLUME TO MOVE THE STOCK PRICE UP ON THE RUN BACK IN FEBRUARY 2013.
I would agree with what many are saying about them diluting shares if they were being added to the tradeable float. The stock price would be very very hard to move up when you have a much larger float. But the FACTS shown in this chart with the price to volume ratio just do not support that the dilution will kill any run up in price. Sorry but it is simply the facts.
Yes SNDY has been selling shares but a lot of people on this board are buying. And this chart tells us that someone is buying them instad of them being dumped in the open market. Booper, Muff1, Blueski, Mgergo, Pennylanepam, Vert, Elcappy1, Frazier, Ichase01, Aqua and many others including myself have been buying millions of shares since February 2012. And the chart says exactly that.
I believe when we get volume of over 750,000,000 in a weeks time we will see this price run back up like it did last year. This time if it is good news driving the price you will have more people coming into buy then before. Last years move was on news of speculation. This time it will be because of what they have achieved in obtaining the CE mark and having a company, EG, that will open up major distribution channels and can help them in getting merger deals done. Also there are many eyes watching on the sidelines to buy this stock because they know just how fast it can run. Let them buyers come in and it can run right past the .024 that was made last year. For that to happen the major longs that do own millions of shares will have to be patience and let the price run. Also last time we had our run the company was selling shares. We know now it looks like they want be selling any share until Feb. 2014. So any price movement this time should not be met with any resistance of the company selling shares.
Now we have to do our part. If we all do own a major chunk of the shares, then we own a very large amount of the float. If we don't sell on the run up then the price will have to run higher because demand will be greater then the the supply of shares available. I believe once we break the .01 mark firmly then we will loose alot of the flippers and we will see the price move quickly from there. All it will take is major news. CE Mark will be starters, then big increase in revenue, along with a merger/buyout right after CE Mark or down the road after sales revenue increase. I still say this has merger/buyout written ALL OVER IT!
Take care my friends,
Mike
Thanks Mike!
blueskies
Here's a great read everybody - it was posted by Boiler1183 not too long ago addressing the CE Mark
BTW We moved up 6 spots in the past hour or so. Keep reading all.
Here are the facts every investor should be considering. This needs to be read and understood by anyone investing in Solos.
As to my accreditation, I personally work for a niche supplier to the aerospace and power-generation industries, and will speak analogously from my experience and knowledge to debunk some of the unnecessary arguments being used to propagate doubt and fear about Solos' business approach. I will present nothing but general knowledge, experience, and facts, and allow the reader to draw their own conclusions.
I have seen the rhetorical question posed several times about how the ISO 13485:2003 and CE mark could possibly improve Solos' market penetration in selling Endoscopic equipment. Such a question shows a clear disconnect from a supplier-based environment. My company makes one specific type of product, and as a supplier you have intermittent customers, your mom-and-pop machine shops and aftermarket consumers, that have "low-standards," if you will. These customers scrape together sales that account for a tiny fraction of our revenue in a given year, on the order of a few hundred thousand dollars . Almost all small suppliers start off in such a market, using their limited manufacturing capabilities and lack of proper certification to please the one-off customers - the research labs and student hospitals, if you will. Sometimes this is enough to grow your capacity to a point where you can afford the next big step, and sometimes additional capital is raised through investors, but one truth remains: the real money is made through the real customers - the multi-billion dollar corporations that account for the majority of the market. Unfortunately, the real customers have higher standards than the one-off customers, and to even be considered as a supplier to the big customers, you must meet certain international standards for quality.
This is the fact that many fail to consider. Being certified to the industry-standard ISO certifications is not a bragging right - it is a REQUIREMENT to even be considered as a supplier when it comes to the big customers. For my company, our millions are made through the aerospace giants of the world, all who require us to be ISO 9001:2008 certified. Receiving and maintaining such certification is incredibly costly and tedious, but without it we would literally not even be considered in the running with the customers who keep our lights on.
What is more, the large customers for specialized products and devices are generally required to diversify their supplier base as to limit their supplier-end risk as a business and to ensure competitive pricing from suppliers. This push for diversification is ongoing and persistent, beneficial both to the customers and the suppliers.
To answer the rhetorical question of "how will this certification impact their ability to penetrate the $100 billion domestic market", my answer is simple. The real customers of any industry, whether it be aerospace, medical, or otherwise, demand certain International Standards for quality (see "ISO"). Such accreditation offers enormous opportunity to capture market share for the exact reasons mentioned. This is not my opinion, this is fact. My company of a few dozen employees thrives in a competitive niche market specifically because we achieved and maintained the Industry Standard quality requirements and, in turn, won sales contracts with the industry giants that account for millions a year in revenue.
As to anyone who doubts Solos' business approach of using their meager revenue and stock offerings to obtain the capital and quality of business necessary to achieve international quality standards, I pose the following question. What business owner with a competent understanding of their market would not strive to meet the requirements necessary to secure the revenue that is offered by the high-end customers?
Just as I have done by investing in Solos' potential, Solos has invested in their potential to secure a portion of the medical device market by achieving the qualifications necessary to supply to the industry giants. Call it whatever you want, this is what is unfolding, and I for one could not agree more with their approach.
Thanks for the insight Boiler1183
Blueskies
$SNDY Making it's way up the breakout boards :) Great job Aqua!
blueskies
picked up another 500k at .005, way oversold here for no reason...good luck all
blueskies
Picking up a bunch more shares today...we are building a nice support here at the .006 level. As the news comes this will resume its trend up IMO.
As the 50 and 200 tighten up we should see a break out up. Fundamentally the company (Trifecta) is growing.
We should also see the Q today or tomorrow.
Blueskies and Good Luck
In all honesty I would not be surprised to see something out this week. The company has a history of doing a few straight weeks of PR's. They just recently did this in August. 8/8, 8/13 Q's, 8/14 Prez letter, 8/22.
We should see the Presidents Letter soon with remarks on the technical files, outlook, etc.
Things are lining up, the pps is holding and regardless of what is said here - everybody knows it's coming; and I believe everybody here has built a very nice position. Good luck to you.
http://www.solosendoscopy.com/press-releases/SNDY-ISO-13485-CE-Mark-Project-Schedule-June-2013.pdf
blueskies
Correction: This keep getting better - We are exactly where we need to be. Check the chart - sitting right at the 50 SMA (006) - No worries in the slightest. Going higher soon
good luck to you
blueskies
I believe news on the CE Mark will follow very very soon along with updates in the Presidents Letter to shareholders.
Blueskies
Quarterly Report is out!
http://www.otcmarkets.com/financialReportViewer?symbol=SNDY&id=113146
blueskies
I think Highflier bought 80 mil in ONE SHOT...nice work
Blueskies
I must say I am pleasantly surprised to see some familiar names here. I actually made my first purchase here 01/12 - before the gold and pools...BUT since the pool business model took over recently ...I've added much more.
blueskies and Good luck
Nice work Aqua!! I was able to load up bigtime under .002 starting on the 3rd of October. I picked up most around the 16's but also some at 17s & 18s. I've definitely built a substantial position here and feel we will realize the benefits of our patience very soon.
Good Luck to you
blueskies
looks like the 18's are coming back - I wish I got some of those 15's
blueskies
Looks like we are back online....37000 volume just went through!
blueskies
...maybe a little bit excited? :)
I realize it's not "the" news..but it's not just fluff either. Nothing has changed with the direction this company is moving. We are still moving forward in the right direction. They are focusing on brand awareness and worldwide sale. They have completed the audits with no non-conformities. IMO the writing is on the wall and we shouldn't ignore the fact
They begin with these PRs that will act as the catalyst to bring the pps up. Soon Ce mark will be in hand, quarterly report due out next week (unless late notification), Presidents letter, possible acquisition/merger/buyout deal.
In my opinion there are many things to be excited about here.
haha that's the great thing about it being my money...I can do whatever I want with it.
I think good things are coming - and the longs that have been hear and have waited in the wings will soon enjoy the benefits.
I open the door now to the others with talks of massive dilution, RS, burn shareholder at the stake, AS, OS, Volume, etc etc etc.
Good luck to you
blueskies
I wish the OTC market would get their act together - it's forcing me to do actual work today. Yikes!!
Wall Street Journal picked up the article
http://online.wsj.com/article/PR-CO-20131107-912202.html?dsk=y
blueskies
Yeah I heard 10am trading would resume but it looks like it may be a bit more time... thats ok...let it sink in. "Solos Endoscopy instruments are FDA approved. Solos Endoscopy intends to place the CE Mark on its entire MammoView® instrument line with proper approval which will allow the instrument line to be sold globally starting in 2014."
This is only the beginning - IMO!!
This is not a company that is trying to screw shareholders - IMO
Investors should be in now - because the PR's ARE beginning
Good luck all, I know everybody on this board is in, I hope we all built on our positions & blueskies
Solos Endoscopy Announces the MammoView(R) Breast Cancer Global Initiative for 2014
BOSTON, MA -- (Marketwired) -- 11/07/13 -- Solos Endoscopy, Inc. (OTC Pink: SNDY) is pleased to announce its new MammoView® Breast Cancer Global Initiative for 2014. Solos Endoscopy plans to work with various breast cancer awareness campaigns year round to continue building upon the public's "brand awareness" for breast cancer; its detection, its treatment, and the need for a reliable, permanent cure.
Increased awareness has resulted in more women receiving mammograms, the number of breast cancers detected, and the number of women receiving biopsies. Solos Endoscopy believes that as a result of awareness, breast cancers are being detected at an earlier, more treatable stage. Awareness efforts have successfully utilized marketing approaches to reduce the stigma associated with the disease.
However, more work needs to be done. As part of the new MammoView® Breast Cancer Global Initiative, Solos Endoscopy plans to team up with the various charities and foundations who are promoting "Breast Cancer Awareness" and educate them about the clinical benefits of the MammoView® instrument line and breast ductoscopy. The Solos Endoscopy MammoView® Breast Endoscopy System can offer women a positive prognosis for recovery by detecting breast cancer up to six times faster than conventional methods. The MammoView® instrument line allows physicians to distinguish and inspect suspicious pre-cancerous lesions undetectable by other methods.
"The MammoView® Breast Cancer Global Initiative is more than just awareness, it's about education, and choices for women. October is over; people and businesses nationwide will take down their pink ribbons and pink signs, yet women all over the world will still be battling breast cancer. Solos Endoscopy will continue its efforts to fight breast cancer not just in October but throughout the year," stated Robert Segersten, President of Solos Endoscopy.
Solos Endoscopy instruments are FDA approved. Solos Endoscopy intends to place the CE Mark on its entire MammoView® instrument line with proper approval which will allow the instrument line to be sold globally starting in 2014.
blueskies
NEWS!!
Solos Endoscopy Announces the MammoView(R) Breast Cancer Global Initiative for 2014
blueskies
not sure...not stated in the PR. I tweeted the question to Clark. I would assume Texas time
blueskies
Special CC TODAY 3:30 - Know what you own!
- all investors should tune in and listen for themselves!
A Special conference call will be held today at 3:30 pm to discuss this corporate movement. All questions for this conference call should be submitted to Clark.Ortiz@SwordfishFinancial.com Participants are invited to call 559-726-1200 Access Code 868001#.
blueskies
A Special conference call will be held today at 3:30 pm to discuss this corporate movement. All questions for this conference call should be submitted to Clark.Ortiz@SwordfishFinancial.com Participants are invited to call 559-726-1200 Access Code 868001#.
I encourage ALL to tune in!!
blueskies
THIS IS THE PLAY!!
SWRF combined with its iPoint Television, LLC, which is within its holdings, provides the bases of all new mediums of business. In today's world, code writing is more than just bits of information combined to run simple programs over a computer. Codes are what make our world work, play and communicate.
blueskies
come on girl...time to show us those .0021's again...
Financials due out next week usless we get a Notice of late filing
blueskies
So true highflier - key point about it's profitability for next year is that NEXT YEAR is right around the corner.
All potential investors that are hesitant about jumping in should seriously tune into the CC's - Clark is a straight up, hard-working business man, with his shareholders in mind constantly.
Thank you again for opening my eyes up to this little diamond. I really wish the other play would begin to make a nice move north. I would love to take a little bit out and put it to work here (trifecta play)...soon though.
It feels as though $SWRF is handling the news the best so far. The moves have been gradual over the past year. I always get concerned when the charts spike "to the moon"
Well... have a great day
thanks again and as many other do, I look forward to reading your posts.
Blueskies and good luck
Just listened to the CC - Very very very exciting things in the making here - I am shocked we are under a penny (but love the fact I can keep adding)- Trifecta ( $SWRF $TDEY $PBHG ) will be HUGE!!!
What has C.Ortiz brought to $SWRF
- iPoint Tv
- 50% income from iPoint TV
- acquisitions of 90% of the units of iPoint TV
- the iPoint app
- iPoint Tv reaching 5mil homes through Roku
- iPoint Tv reaching 100k homes mobile applications
- brought 50% of App3dtv to $SWRF
- Take (non-digital) the art world and covert it digitally!
"increase income, cash flow, profitability and share holder value!"
"this is the final build block of this enterprise!!"
if you are a share holder, you are apart of the "tidal wave that will take the digital world by storm"
Tomorrow morning expect more news!
$TDEY CC Thursday! - tune in
this CEO Rocks!!
blueskies
Agreed! I am shocked we are under a penny (but love the fact I can keep adding)- Trifecta ( $SWRF $TDEY $PBHG ) will be huge
What has C.Ortiz brough to $SWRF
- iPont Tv
- 50% income from iPoint TV
- acquisitions of 90% of the units of iPoint TV
- the iPoint app
- iPoint Tv reaching 5mil homes through Roku
- iPoint Tv reaching 100k homes mobile applications
- brought 50% of App3dtv to SWRF
- Take (non-digital) the art world and covert it digitally!
"increase income, cash flow, profitability and share holder value!"
"this is the final build block of this enterprise!!"
if you are a share holder, you are apart of the "tidal wave that will take the digital world by storm"
Tomorrow morning expect more news!
$TDEY CC Thursday! - tune in
this CEO Rocks!!
blueskies